Antibody

An antibody is a protein that recognizes particular molecular targets through binding. Antibodies participate in immunity; laboratory assays such as Western blots exploit their selective binding to detect chosen proteins.

An IgG gives a concrete architecture: two immunoglobulin heavy chains and two immunoglobulin light chains, joined by disulfide bonds. Each arm ends in a paratope assembled from an antibody variable region of each kind of chain. The two paratopes recognize the same epitope in this conventional IgG; the flexible hinge allows different arm separations. The antibody constant regions form the remaining portions. This is an illustrative IgG, rather than the architecture of every antibody format. ^[ref]

Three questions must be kept separate. Antibody specificity asks which antigens are recognized. Antibody affinity describes one paratope–epitope interaction. Avidity describes the combined attachment when several contacts can cooperate. A selective antibody can have modest antibody affinity, and a monoclonal antibody can still show cross-reactivity. For an assay, the practical question is whether the observed readout identifies the intended antigen under the tested conditions; Western blot antibody specificity controls make that question concrete.

An antibody possessing catalytic activity. Selection against a stable transition-state analogue can produce rate enhancement, but affinity for an analogue alone does not guarantee rapid turnover or product release.

An antibody linked to a cytotoxic payload for targeted delivery to antigen-bearing biological cells. Binding, uptake, linker stability and drug release all influence selectivity.

Antibody phage display displays antibody fragments on phage particles carrying their encoding sequences. Binding selection enriches candidates while maintaining genotype–phenotype linkage, followed by testing in soluble and intended therapeutic formats.

Hybridoma technology combines an antibody-producing primary cell with an immortal cell line to establish continued production of a chosen antibody. Fusion-product survival and antigen specificity require separate selection and screening steps.

In an indirect Western blot, the primary antibody binds an epitope on the proposed target protein. Its binding must be tested in the actual sample and assay conditions through Western blot antibody specificity controls.

A secondary antibody recognizes another antibody, rather than the proposed target protein directly. In Western blot antibody detection, its attached label makes retained primary antibodies visible. A secondary antibody must recognize the kind of primary antibody used.

An epitope is the molecular feature recognized by an antibody. Protein denaturation can expose an epitope or destroy the spatial arrangement required for its recognition; an antibody that works on a folded protein need not work in SDS-PAGE-based Western blot antibody detection.

Epitope mapping investigates which target regions or residues contribute to recognition by an antibody. Loss of binding after a target mutation must be distinguished from target misfolding or loss of expression.

Immunoglobulin G is an antibody class whose conventional four-chain architecture supplies the example above.

An ordinary IgG has two matching immunoglobulin heavy chains and two matching immunoglobulin light chains, abbreviated $H_2{L}_2$. Its gamma-type immunoglobulin heavy chains contribute both to recognition and to interactions with immune partners.^[ref]

A useful way to read this picture is to follow a single polypeptide chain continuously from its N-terminus to its C-terminus, then examine the crosslinks separately. The same immunoglobulin heavy chain contributes to a Fab fragment and to the Fc fragment; these named fragments are not pre-existing separate chains. Conversely, one Fab fragment contains material from two different chains. The protein primary structure and the fragment inventory therefore answer different questions about the same protein.

Gerald M. Edelman reduced IgG disulfide bonds and used dissociating chemical solutions, including $6\mathrm{mol}{\mathrm{L}}^{-1}$ urea. Ultracentrifugal analysis showed a decrease in molar mass, supporting a multichain protein. In the comparison reproduced in his lecture, starch gel electrophoresis in urea separated serum IgG and a urinary protein from the same patient, alongside their reduced and alkylation-treated preparations. The untreated samples provided the treatment comparison; the urinary material provided a chain-identity comparison. The treated serum sample revealed heavy- and light-chain bands. Two-dimensional peptide mapping compared the urinary protein with the isolated immunoglobulin light chain. Together these readouts supported a shared chain identity.^[ref]

The controls address distinct alternatives. Treatment-dependent separation supports chains joined in the starting protein; a matching gel electrophoresis position alone would not uniquely identify a chain. Agreement of peptide mapping adds an independent chemical comparison. Neither readout gives atomic coordinates, and this patient's preparation does not establish a common protein primary structure for all antibodies.

Reduction targets protein disulfide bonds, while protein denaturation weakens the folded assembly. Neither operation is the proteolysis that cuts peptide bonds. This explains why chain separation and Papain digestion of IgG give different inventories: four intact chain backbones in the first case, three assembled fragments in the second.

The antibody hinge region is a flexible IgG immunoglobulin heavy chain segment between $C_{H1}$ and $C_{H2}$ containing inter-heavy-chain disulfide bonds.^[ref]

An immunoglobulin heavy chain extends through an arm and the stem of the illustrated IgG.

Its IgG protein domains run from the N-terminus as $V_H,C_{H1},C_{H2},C_{H3}$: the first pair contributes to Fab fragments, the last pair to the Fc fragment.^[ref]

An immunoglobulin light chain accompanies an arm of the illustrated IgG, contributing to its paratope.

Its protein domains are $V_L,C_L$, read from the N-terminus; a Fab fragment retains both.^[ref]

The paired antibody variable regions of an immunoglobulin heavy chain and an immunoglobulin light chain contribute to an antibody binding site. Variation refers to differences between antibody sequences, not to a tip continually changing identity while binding.

A complementarity-determining region is a variable-region segment contributing to an antibody binding site. Transfer of these regions can transfer specificity, but framework residues also influence conformation and affinity.

An antibody constant region is a chain portion outside the antibody variable region. Constant does not mean identical across every antibody class.

A Fab fragment contains one antibody binding site, allowing comparison with the two-site intact IgG in the antibody surface plasmon resonance experiment.

A Fab fragment combines one complete immunoglobulin light chain with one immunoglobulin heavy chain $V_H,C_{H1}$ portion, including antibody constant regions.^[ref]

The single paratope makes a Fab fragment useful for separating antibody affinity from two-arm avidity. If an intact IgG attaches strongly to a surface but its matched Fab fragments detach more readily, loss of the second arm is a candidate explanation even if the individual paratope is unchanged. Comparing the formats asks a structural question; it does not by itself establish which binding mechanism dominates.

Limited Papain digestion of IgG cuts each immunoglobulin heavy chain on the N-terminus side of the hinge crosslinks, releasing two Fab fragments and one Fc fragment.^[ref]

A connectivity argument explains the three products. Treat each continuous backbone segment as a graph vertex, and retained interchain disulfide bonds as edges. After the two stipulated cuts, six backbone segments remain: two complete immunoglobulin light chains, two immunoglobulin heavy chain arm segments and two immunoglobulin heavy chain stem segments. Each light chain remains attached to its own arm segment, producing two separate Fab fragments. The two stem segments remain attached to each other, producing one Fc fragment. Thus six backbone segments form three connected components of a graph, not six independently released products. Removing crosslinks instead, while keeping each backbone intact, would leave four chain components in this simplified covalent-connectivity model.

For a constructed mixture, start with $5\mathrm{pmol}$ of intact IgG and stipulate that $60\%$ undergoes the complete two-cut event while the rest remains intact. Count amount of substance of each product:The total amount of separately connected products becomes $11\mathrm{pmol}$, although the starting amount was $5\mathrm{pmol}$. Each digested IgG replaces one connected assembly with three. The antibody binding site inventory is conserved in this model:The factor two counts sites per intact IgG, not extra immunoglobulin light chains per Fab fragment. Fragment counts, backbone-segment counts and antibody binding site counts must be kept distinct. A real digest's retained binding would additionally depend on preservation of the paratopes.

The historical functional test was more subtle than asking whether a fragment still formed a visible precipitate. Rodney Robert Porter's earlier rabbit anti-ovalbumin preparation was digested with papain powder. The resulting fragment did not precipitate ovalbumin itself, but specifically inhibited ovalbumin precipitation with undigested antiserum. The intact-antiserum reaction supplied the positive comparison: failure to precipitate alone did not mean failure to recognize the antigen.^[ref]

The inference is that binding and assembly of a precipitating network are different abilities. A one-site Fab fragment can occupy an epitope without providing the two-arm bridge available to intact IgG. The inhibition readout supports retained recognition under the tested conditions; it does not locate individual contacts or show that every papain-generated product binds. This is the conceptual benefit of fragmenting an antibody: one can ask which functions survive loss of a structural connection.

The Fc fragment comprises paired immunoglobulin heavy chain $C_{H2},C_{H3}$ portions, interacts with immune partners and lacks paratopes. Its name records historical crystallization.^[ref]

For example, Fc fragments can bind components of the complement system, illustrating a function distinct from epitope recognition.^[ref]

An isolated Fc fragment therefore separates one set of protein interactions from target recognition. In the connectivity example under Papain digestion of IgG, the Fc fragment contributes one connected product but zero antibody binding sites. Retaining it preserves different interaction surfaces; it does not restore either severed arm. Conversely, the two Fab fragments preserve the stipulated epitope-recognition sites while losing their connection to this common stem.

A paratope is the recognizing surface on an antibody; the epitope is the recognized feature on its antigen. Contacts depend on spatial arrangement and chemistry, including hydrogen bonds and Van der Waals forces. Thus a paratope is not simply a slot for a protein primary structure string. A folded protein can bring distant amino acid residues into one epitope. ^[ref]

In antibody binding, an antigen is material bearing a recognized epitope. An antigen need not be a protein; polysaccharides can also carry epitopes. One antigen may present several different epitopes, so recognizing one feature does not imply recognizing every part of the target. ^[ref]

An antigen arising from a tumour-associated alteration, potentially providing selective immune recognition. Mutation detection alone does not demonstrate processing, presentation or immunogenicity.

An antigen associated with malignant cells that can also be expressed in normal tissues. Association with a tumour is not proof of tumour-specific expression.

Antibody specificity describes preferential recognition of selected epitopes. It is established relative to tested alternatives and assay conditions, rather than inferred from a reagent's name. Western blot antibody specificity controls distinguish recognition of the proposed protein from retained label caused by other material.

Cross-reactivity occurs when an antibody also recognizes another antigen beyond the one against which it was raised. This may involve related features, but obvious overall similarity is not required. ^[ref]

For an imagined example, a paratope contacts a small surface patch shared by two otherwise different proteins. Both can bind even though their remaining surfaces differ. Increasing antibody concentration can reveal weak binding that was previously undetectable. Conversely, an extra Western blot band need not prove cross-reactivity: the intended protein may occur in multiple forms, or detection reagents may contribute background. The target-deleted and no-primary antibody comparisons under Western blot antibody specificity controls test different explanations.

A monoclonal antibody preparation derives from one selected antibody-producing biological cell and its descendants, or reproduces their specified antibody sequences. Monoclonal describes the origin and composition of the preparation; it does not guarantee absence of cross-reactivity or establish antibody affinity. ^[ref]

Avidity is the combined strength of multivalent attachment. An intact IgG can make two contacts when accessible epitopes have suitable spacing. ^[ref] If one contact breaks while the other remains, the detached arm stays nearby and can bind again before the whole antibody escapes. That geometric advantage does not require changing either paratope's intrinsic antibody affinity. Two arms binding two separate freely moving antigens do not automatically provide the same tethering advantage. Epitope spacing, accessibility and surface density matter; avidity is not obtained by adding two dissociation constants.

The concentration-equivalent measure of how a tethered group is presented to a second binding site. Geometry, linker flexibility and accessibility affect the probability of forming an additional contact.

Antibody affinity concerns one paratope binding one epitope. A Fab fragment supplies a single-site comparison. ^[ref] In the dilute chemical equilibrium model below, smaller dissociation constant $K_d$ means larger antibody equilibrium occupancy at the same free antigen concentration. State the antigen, temperature and buffer solution: a dissociation constant is not a context-free score. It does not alone specify how fast attachment or detachment occurs.

Affinity maturation improves antigen-binding performance through sequence variation and selection. In engineered antibodies it must be assessed alongside specificity, folding, aggregation and the effects of multivalent avidity.

Antibody equilibrium occupancy counts occupied antibody binding sites, rather than retained assay label. For an original 1:1 model, let $A$ denote an unoccupied site, $E$ free antigen bearing one accessible epitope, and $AE$ their complex. At chemical equilibrium, writeSquare brackets mean concentrations. The dissociation constant $K_d$ here has concentration units. This is the same independent-site calculation as receptor binding occupancy, now applied to an antibody binding site. The last equality follows by substituting $[AE]=[A]c/K_d$ into the occupied fraction and cancelling $[A]$.

Assume identical independent sites, reversible 1:1 binding, dilute chemical solution behavior, fixed temperature and buffer solution, and enough time for chemical equilibrium. Exclude two-arm bridging, cross-reactivity and inaccessible sites from this model. Crucially, $c$ is free antigen concentration; substituting the amount supplied per volume requires negligible depletion by binding. Independent IgG arms could obey this model site by site, but it does not describe avidity from bridging a surface.

Stipulate $K_d=20\mathrm{nM}$, with $1\mathrm{nM}=10^{-9}\mathrm{mol}{\mathrm{L}}^{-1}$. Free antigen concentrations $2$, $20$ and $200\mathrm{nM}$ give $\theta =1/11$, $1/2$ and $10/11$. A second stipulated dissociation constant of $200\mathrm{nM}$ instead gives $\theta =1/11$ at $c=20\mathrm{nM}$. Both curves approach one at large $c$: a nearly saturated readout can conceal an antibody affinity difference. These are invented values, with no universal threshold for a useful antibody.

A Western blot readout additionally depends on Western blot transfer, accessible epitopes, loss during washing and Western blot antibody detection. Western blot response saturation can flatten the final signal even when binding itself remains responsive. An ELISA also reports retained label through an enzyme readout, rather than automatically reporting $\theta$. Thus half of an assay's maximum signal need not occur at $c=K_d$. Varying free antigen through concentrations near the candidate dissociation constant, while checking depletion and the readout's response, is more informative than comparing a single saturated point.

A concrete comparison used a Biacore T100 with a CM5 chip bearing the target receptor; unused reactive surface groups were blocked. At $25{}^{\circ }\mathrm{C}$ in a pH 7.4 buffer solution, intact IgG and its Fab fragment were injected for $180\mathrm{s}$ at $5\mu \mathrm{L}/\min$; dissociation was monitored for $3600\mathrm{s}$. The optical response tracks changes in refractive index near the surface, rather than counting occupied paratopes directly. A reference surface and blank injections corrected background; association and dissociation responses were fitted with a 1:1 model. The reported intact-IgG detachment was slower than that of the Fab fragment. ^[ref]

This comparison supports format-dependent attachment, not an intrinsic single-site antibody affinity for intact IgG. The reference and blanks address background, not two-arm avidity, surface accessibility or delivery by diffusion. The paper's fitted 1:1 constants alone cannot distinguish those mechanisms. Its Fab fragment comparison therefore motivates specifying the binding format before interpreting a dissociation constant; a good fit does not establish a unique molecular model.